Future growth expectations in earnings/operating earnings/profits/EPS?

Operating EBITDA margin expected to sustain at about 32.5% in Q4 FY25. Full year FY25 operating EBITDA margin is anticipated to improve to around 32.5% from 31.4% last year (110 bps improvement). Margin improvement guidance of 50 to 100 basis points per year expected to continue going forward. FY26 margin to improve by 50 to 100 bps, driven by branded segment contribution and expected US launches reducing negative contribution. Insulin business expected to return to normal run rate (Rs. 75-80 crore per quarter) plus spillover revenue in Q4. Brazil to continue double-digit constant cu

Any current/future new fundraising through debt or equity?

No explicit mention of any new fundraising through debt or equity in the current quarter or near future. Sudhir Menon indicated that the company expects to become net cash positive by H1 FY27 due to ongoing repayments. Interest expenses are expected to continue decreasing quarter-on-quarter because of these repayments. Discussions on capital allocation priorities are still a work in progress, with more clarity expected in a couple of quarters. The company prioritizes investments in India branded generics, followed by selective opportunities in international developed markets. No specific plans

Any current/future capex/capital investment/strategic investment?

Sudhir Menon mentioned that the company's capital allocation priorities and strategic investments are still a work in progress, with specific details expected in a couple of quarters. The top priority for capital allocation remains India, especially branded generics, where the company has the best track record and highest comfort. They remain open to opportunities in developed markets like Germany and the US in specified areas. There was mention of reinvestment happening in the branded business which could impact margin improvements, indicating ongoing or planned investments. The company is al

Future growth expectations in sales/revenue/volumes?

India business continues to outperform market growth with 12-13% revenue growth YTD; focus on cardiac, diabetes, and gastro drives growth. Chronic business in India grew 14% vs. IPM 10%, aided by new product launches and expanded field force. Brazil market expected to maintain double-digit growth (~10-12% constant currency); government price hikes anticipated to offset currency depreciation. Germany business to see growth from new tenders starting Q2 next year; expect continued high single-digit growth. US business stable but slow pickup expected short-term; growth dependent on new AND

Current/ Expected Orderbook/ Pending Orders?

The document does not explicitly mention the current or expected order book or pending orders for Torrent Pharmaceuticals. However, highlights on product launches and market expectations are noted: - In Brazil and India, plans to launch GLP-1 products are aligned with patent expiry in March 2026, aiming to be in the first wave of launches. - Brazil has a rich pipeline of 20 molecules filed and awaiting ANVISA approval. - Germany business won incremental new tenders starting to contribute from Q2 FY26. Focus remains on market formation activities and education for new products, indicating

IN US

Sale is live|00:00:00left today

Torrent Pharmaceuticals LtdQ4 FY26Pharmaceuticals & Biotechnology

Torrent Pharmaceuticals Ltd Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹4,571P/E: 64.7Market Cap: ₹1.5L CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 2 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→India business continues to outperform market growth with 12-13% revenue growth YTD; focus on cardiac, diabetes, and gastro drives growth.
→Chronic business in India grew 14% vs. IPM 10%, aided by new product launches and expanded field force.
→Brazil market expected to maintain double-digit growth (~10-12% constant currency); government price hikes anticipated to offset currency depreciation.
→Germany business to see growth from new tenders starting Q2 next year; expect continued high single-digit growth.
→US business stable but slow pickup expected short-term; growth dependent on new ANDA filings.
→Overall, company projects 7% underlying revenue growth normalized for insulin business and currency impact in Q3.
→Operating EBITDA margin expected to improve 50-100 bps annually, supported by branded business growth and US launches next year.
→Insulin business expected to recover with Q4 showing spillover above Rs. 75-80 crore quarterly run rate.

Margin guidance

Category 3

→Operating EBITDA margin expected to sustain at about 32.5% in Q4 FY25.
→Full year FY25 operating EBITDA margin is anticipated to improve to around 32.5% from 31.4% last year (110 bps improvement).
→Margin improvement guidance of 50 to 100 basis points per year expected to continue going forward.
→FY26 margin to improve by 50 to 100 bps, driven by branded segment contribution and expected US launches reducing negative contribution.
→Insulin business expected to return to normal run rate (Rs. 75-80 crore per quarter) plus spillover revenue in Q4.
→Brazil to continue double-digit constant currency growth with expected government price revisions in April 2025.
→India branded business to continue outperforming market growth (~12-13% YTD) with focus on cardiac, diabetes, gastro.
→Net debt to EBITDA expected to reduce, with company likely to turn net cash positive by first half FY27.

3 more insights locked — sign up free to unlock

Fundraise plans

→No explicit mention of any new fundraising through debt or equity in the current quarter or near future.
→Sudhir Menon indicated that the company expects to become net cash positive by H1 FY27 due to ongoing repayments.
→Interest expenses are expected to continue decreasing quarter-on-quarter because of these repayments.
→Discussions on capital allocation priorities are still a work in progress, with more clarity expected in a couple of quarters.
→The company prioritizes investments in India branded generics, followed by selective opportunities in international developed markets.
→No specific plans or announcements regarding raising fresh debt or equity were disclosed during the call.

Order book

→The document does not explicitly mention the current or expected order book or pending orders for Torrent Pharmaceuticals.
→However, highlights on product launches and market expectations are noted:
→ - In Brazil and India, plans to launch GLP-1 products are aligned with patent expiry in March 2026, aiming to be in the first wave of launches.
→ - Brazil has a rich pipeline of 20 molecules filed and awaiting ANVISA approval.
→ - Germany business won incremental new tenders starting to contribute from Q2 FY26.
→Focus remains on market formation activities and education for new products, indicating pipeline and upcoming opportunities.
→No specific quantitative data on order book or pending orders provided during the Q3 FY25 call.

Capex plans

→Sudhir Menon mentioned that the company's capital allocation priorities and strategic investments are still a work in progress, with specific details expected in a couple of quarters.
→The top priority for capital allocation remains India, especially branded generics, where the company has the best track record and highest comfort.
→They remain open to opportunities in developed markets like Germany and the US in specified areas.
→There was mention of reinvestment happening in the branded business which could impact margin improvements, indicating ongoing or planned investments.
→The company is also making investments in market formation activities such as information dissemination and education for new product launches.
→No specific new capex or strategic transaction details were disclosed at this stage.

How does Torrent Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Torrent Pharmaceuticals Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Torrent Pharmaceuticals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio